What Has Been The Evolution of the Oral Transmucosal Drugs Market in Recent Years?
The oral transmucosal drugs market has seen considerable growth due to a variety of factors.
• The oral transmucosal drugs market has experienced strong growth. It is projected to rise from $39.7 billion in 2024 to $43.53 billion in 2025, at a compound annual growth rate (CAGR) of 9.6%.
Growth factors include advancements in diagnostic capabilities, an aging population, environmental pollutants, genetic susceptibilities, better detection rates, and faster drug absorption leading to improved patient compliance.
What Is the Forecasted Market Size and Growth Rate for The Oral Transmucosal Drugs Market Size In The Coming Years?
The oral transmucosal drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The oral transmucosal drugs market is projected to grow to $62.03 billion by 2029, at a CAGR of 9.3%.
Growth is driven by advancements in personalized medicine, new drug delivery systems, an aging population, increasing awareness of oral health, and regulatory changes. Major trends include novel drug formulations, personalized medicine approaches, telehealth advancements, and integration of digital health technologies.
What Factors Are Driving Growth In The Oral Transmucosal Drugs Market?
The escalation in cases of Parkinson's disease is anticipated to drive the expansion of the market for oral transmucosal drugs. Parkinson's disease is a progressive neurological disorder characterized by trembling, rigidity, and motor challenges, resulting from a decrease in dopamine-producing cells in the brain. The increasing occurrence of this condition is attributed to factors such as older population, environmental contaminants, genetic predispositions, and improved diagnostic methods that heighten detection rates. Oral transmucosal medications contribute to Parkinson's disease management by encouraging rapid drug uptake and overcoming digestive issues, resulting in quicker relief, improved compliance, and potentially fewer motor complications. For example, as of December 2022, approximately 1 million individuals in the US are afflicted with Parkinson's disease (PD), as per the Parkinson's Foundation, a US-based non-profit group. This figure is forecasted to rise to 1.2 million by 2030. Consequently, the escalating cases of Parkinson's disease are fueling the growth of the oral transmucosal drug market.
What Are The Main Segments Of The Global Oral Transmucosal Drugs Market?
The oral transmucosal drugs market covered in this report is segmented –
1) By Product Type: Tablets, Films, Liquid And Spray, Other Product Types
2) By Indication: Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disorders, Other Indications
3) By Route Of Administration: Sublingual Mucosa, Buccal Mucosa, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Tablets: Buccal Tablets, Sublingual Tablets, Effervescent Tablets
2) By Films: Buccal Films, Sublingual Films, Mucoadhesive Films
3) By Liquid And Spray: Sublingual Liquid Solutions, Oral Sprays (Pain Relief, Sleep Aids), Mucosal Gels
4) By Other Product Types: Lozenges, Pastilles, Chewing Gums
Pre-Book The Oral Transmucosal Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Oral Transmucosal Drugs Market?
Leading firms in the oral transmucosal medication market are concentrating on creating progressive drug delivery options, such as the sublingual vitamin spray, in an effort to amplify the potency of drug delivery, increase patient compliance, and maximize the results of treatments. The sublingual vitamin spray, an oral transmucosal medication delivery mechanism, carries vitamins straight into the bloodstream through the mucosal tissues beneath the tongue. This approach skirts the gastrointestinal tract and liver metabolism, making vitamin uptake swift and effective. As an illustration, in October 2022, Vestige Marketing, a wellness and fitness enterprise based in India, launched Absorvit, a sublingual vitamin spray that ensures fast absorption and instant outcomes. This groundbreaking product achieves 3–10 times more uptake compared to conventional oral techniques. The spray comprises upgraded types and precise quantities of key vitamins, including B12, C, D, and multivitamins, ensuring optimal delivery of nutrition. Absorvit serves as a handy, productive means of supplementing critical nutrients, thereby boosting general wellbeing.
Who Are the Key Players In The Oral Transmucosal Drugs Market?
Major companies operating in the oral transmucosal drugs market are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi-Aventis LLC
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly & Company Ltd.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Actavis Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Endo Pharmaceuticals Inc.
• Lupin Limited
• Zydus Lifesciences Limited
• Mallinckrodt Pharmaceuticals Plc
• Glenmark Pharmaceuticals Limited
• Jubilant Life Sciences Limited
• Torrent Pharmaceuticals Ltd.
• Alembic Pharmaceuticals Ltd.
• Wockhardt Ltd.
What Is The Most Dominant Region In The Oral Transmucosal Drugs Market?
North America was the largest region in the oral transmucosal drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
